[Clinicopathological analysis of primary intestinal non-Hodgkin's lymphoma: a report of 32 cases].
OBJECTIVE
To investigate the clinical and pathological features and prognostic factors of primary intestinal non-Hodgkin's lymphoma (NHL).


METHODS
Thirty-Two cases of intestinal NHL were studied clinically and pathologically. All cases were reclassified according to the WHO classification of lymphoma in 2001.


RESULTS
Twenty-one cases (65.6%) were diagnosed as B-cell lymphomas, including 15 cases of diffuse large B-cell lymphoma, 2 cases of mantle cell lymphoma, 1 case of follicular lymphoma, 2 cases of MALT lymphoma and 1 case of Burkitt's lymphoma. Ten cases (31.2%) were diagnosed as T cell lymphomas, including 2 enteropathy-associated T cell lymphomas (EATCL) and 8 cases non-EATCL. One case (3.1%) was diagnosed as histiocytic lymphoma. Nine cases were at stage I-II and 23 cases were at stage III-IV. Follow-up information was available in all cases ranging from 4 to 168 months (mean 25.6 months). Fifteen cases died of the disease. The mortality rates were 33% for B cell lymphoma and 80% for T cell neoplasms. Based on Cox multivariate analysis, the clinical stage and histological types of the disease were important prognostic factors (P < 0.05). T cell lymphoma had a relatively poor prognosis.


CONCLUSIONS
Diffuse large B cell lymphoma is the most common subtype of primary intestinal lymphomas. Colon is the most common site involved, followed by the small intestine. Early stage of the disease and low-grade lymphoma appear to have a better prognosis. T cell lymphoma has a very poor prognosis.
Yang
Di
D
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Bai
Chun-mei
CM
Xiao
Yu
Y
Chen
Jie
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007414:Intestinal Neoplasms / Q000473:pathology* / Q000628:therapy; D016393:Lymphoma, B-Cell / Q000473:pathology / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology* / Q000628:therapy; D016399:Lymphoma, T-Cell / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate